Use of SBRT in Treating Pancreatic Cancer

Video

This video highlights the evolution of stereotactic body radiation therapy in the treatment of pancreatic cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Sarah E. Hoffe, MD, of the Moffitt Cancer Center in Tampa, Florida, discusses the evolution of stereotactic body radiation therapy (SBRT) for the treatment of pancreatic cancer.

      Hoffe also highlights a recent study published in Lancet Oncology using a genomic-adjusted radiation dose (GARD) in patients with various malignancies, a method that could individualize radiotherapy treatment.

      Recent Videos
      Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
      Genetic Data May Inform Personalized Radiotherapy Strategies for Cancer Care
      Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
      Molecular Diagnostics, PIPAC Appear "Exciting" in GI Cancer Surgical Care
      Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
      Prospective Study May Clarify PTEG Benefits in Malignant Bowel Obstruction
      Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
      PTEG Elicits Encouraging Technical Outcomes in Malignant Bowel Obstruction
      Data Show Underutilization of Appendectomy in Appendix Cancer Population
      Data Show Underutilization of Appendectomy in Appendix Cancer Population
      Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
      Novel Treatments May Have the Potential to Impact GI Cancer Care
      Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
      Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
      Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
      Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
      Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
      CRC Yields Most Prevalent Data at Recent GI Meeting
      No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
      No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
      Related Content
      3 Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

      3 Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

      ONCOLOGY Staff
      April 17th 2025
      Article

      Immunotherapy combinations and targeted therapy options may help bridge clinical gaps in early-stage, locally advanced, and metastatic gastroesophageal adenocarcinomas.

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

      Marwan G. Fakih, MD
      February 24th 2025
      Podcast

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years and older.

      Pancreatic/Colorectal Adenocarcinoma Rates Have Increased in Young Adults

      Roman Fabbricatore
      April 15th 2025
      Article

      Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years or older.

      A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

      Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

      Kelley A. Rone, DNP, RN, AGNP-c
      December 2nd 2024
      Podcast

      A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

      Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC

      Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC

      Ashley Chan
      April 12th 2025
      Article

      Post hoc analysis of the NAPOLI 3 trial suggests that proactively managing NALIRIFOX-induced diarrhea could allow patients with PDAC to remain on treatment longer.

      FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

      FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

      Ariana Pelosci;Tim Cortese
      April 11th 2025
      Article

      Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.